Study DEARhealth: ovarian cancer
Study Leveraging DEARhealth Care Management Platform for Ovarian Cancer Care Launched
Collaborative study supported by GSK to assess potential improvement to standard of care will be led by University of California Cancer Consortium
Los Angeles, Calif., 26th of October, 2022 – DEARhealth Inc., a health tech company focused on patients with a chronic condition and their continuous care management, announced today the launch of a randomized, multi-center, controlled study to assess the efficacy of DEARhealth's risk-based care management platform in improving the health of women with ovarian cancer.
The study "Value-Based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)" will be led by the University of California (UC) Cancer Consortium, a collaboration of UC's five National Cancer Institute-designated Comprehensive Cancer Centers. The study is part of the GSK supported studies program and the company's Patient Empowerment Alliance (P.E.A.), an innovative program created to help test, measure, and validate tools that show potential to empower patients as core members of their oncology care team with the goal of improving care outcomes.
Gynecologic oncologists at each UC Cancer Center will direct the study, which follows a successful feasibility study at UCLA Jonsson Comprehensive Cancer Center, which was led by Joshua G. Cohen, MD, a gynecologic oncologist formerly at the David Geffen School of Medicine at UCLA. Dr. Tiffany Lai, Assistant Professor in gynecologic oncology at UCLA will serve as the Principal Investigator. Co-Principal Investigators at each UC Cancer Center includes Drs. Lee-May Chen (UCSF), Pratibha Binder (UCSD), Jill Tseng (UCI), Hui (Amy) Chen and Rebecca Brooks (UC Davis), and Cortney Eakin (UCLA).
"We're excited to embark on this important study that we hope will show the benefits of a harmonized care pathway for ovarian cancer accessible through the DEARhealth care management platform," said Dr. Daniel Hommes, MD, PhD, and Co-founder of DEARhealth.
"GSK is pleased to provide funding to support the UC Cancer Consortium, leveraging DEARhealth's innovative technology, as part of our Patient Empowerment Alliance," said Shannon Altimari, Global Head of Oncology Advocacy to Outcomes, GSK. "The P.E.A. is a novel component of our supported studies program that applies scientific rigor to the assessment of technologies, platforms, and interventions, which may have a positive impact on patient engagement and outcomes."
DEARhealth's care management platform offers risk-based care pathway recommendation functionality with the input of data from electronic medical record (EMR) systems, to support provider teams, patients, and their caregivers in the management of chronic conditions. Recommendations are focused on the Triple Aim: enhancing experiences, improving outcomes, and managing costs. The DEARhealth platform uses clinical data and continuously captured patient-reported outcome measures (PROMs), including those related to disease progression, medications, and mental health, to assess patients and deliver recommendations to adjust the treatment to new developments in a patient's health status. The study aims to deliver evidence-based care recommendations to providers and patients in real-time.
Participants in the study will need to opt-in to data sharing from their UC electronic medical record as part of consent for the trial. All patient data will be securely encrypted for patient privacy.
DEARhealth is a health tech company founded in 2013, by senior University of California, Los Angeles (UCLA) medical experts to transform healthcare by using risk-based care pathways for chronic disease care management. DEARhealth is a validated, software as a medical device, whose partners include health systems, providers, payers, and pharmaceutical companies globally. Investors in DEARhealth include Philips Health Technology Ventures, Vesalius Biocapital III and Health Innovations. To learn more about DEARhealth visit www.dearhealth.com or contact email@example.com.
Download this press release as PDF file [119 kB]